mitomycin has been researched along with bortezomib in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Cassidy, J; Hochster, H | 1 |
| Bartlett, DL; Choudry, HA; Dilly, AK; Kwon, YT; Lee, YJ; Song, X | 1 |
| Chng, WJ; Chow, EK; Ho, CM; Ho, D; Hooi, L; Jha, S; Karnani, N; Rashid, MBMA; Silva, A; Tan, PF; Teh, AL; Toh, TB; Zhang, Y | 1 |
2 review(s) available for mitomycin and bortezomib
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
New oxaliplatin-based combinations in the treatment of colorectal cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Boronic Acids; Bortezomib; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Gefitinib; Humans; Irinotecan; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Pyrazines; Quinazolines; Thiophenes | 2003 |
3 other study(ies) available for mitomycin and bortezomib
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Hypoxia Promotes Synergy between Mitomycin C and Bortezomib through a Coordinated Process of Bcl-xL Phosphorylation and Mitochondrial Translocation of p53.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; bcl-X Protein; Bortezomib; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Mice; Mitochondria; Mitomycin; Phosphorylation; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2015 |
Optimizing drug combinations against multiple myeloma using a quadratic phenotypic optimization platform (QPOP).
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Decitabine; DNA Damage; DNA Methylation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; High-Throughput Screening Assays; Humans; Mice; Mitomycin; Multiple Myeloma; Phenotype; Protein Tyrosine Phosphatase, Non-Receptor Type 6; RNA, Messenger; Tumor Burden | 2018 |